UY35500A - Indazoles sustituidos con heteroarilo - Google Patents

Indazoles sustituidos con heteroarilo

Info

Publication number
UY35500A
UY35500A UY0001035500A UY35500A UY35500A UY 35500 A UY35500 A UY 35500A UY 0001035500 A UY0001035500 A UY 0001035500A UY 35500 A UY35500 A UY 35500A UY 35500 A UY35500 A UY 35500A
Authority
UY
Uruguay
Prior art keywords
indazols
heteroarilo
replaced
drugs
compounds
Prior art date
Application number
UY0001035500A
Other languages
English (en)
Inventor
Dr Wilhelm Bone
Dr Hans Briem
Dr Gerhard Siemeister
Dr Marion Hitchcock
Dr Anne Mengel
Dr Knut Eis
Dr Amaury Ernesto Fernandez-Montalvan
Dr Vera Pütter
Dr Simon Holton
Dr Cornelia Preusse
Dr Jens Schröder
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY35500A publication Critical patent/UY35500A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Compuestos de la fórmula (I). que son inhibidores de Bub1 quinasa; procesos para su producción y s u uso como fármacos.
UY0001035500A 2013-03-21 2014-03-24 Indazoles sustituidos con heteroarilo UY35500A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13160520 2013-03-21

Publications (1)

Publication Number Publication Date
UY35500A true UY35500A (es) 2014-10-31

Family

ID=47901890

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035500A UY35500A (es) 2013-03-21 2014-03-24 Indazoles sustituidos con heteroarilo

Country Status (10)

Country Link
US (1) US20160046610A1 (es)
EP (1) EP2976336A1 (es)
JP (1) JP2016514718A (es)
CN (1) CN105209455A (es)
AR (1) AR095706A1 (es)
CA (1) CA2907592A1 (es)
HK (1) HK1218750A1 (es)
TW (1) TW201514166A (es)
UY (1) UY35500A (es)
WO (1) WO2014147203A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
JP6141866B2 (ja) 2011-12-21 2017-06-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換ベンジルピラゾール類
US20160046604A1 (en) * 2013-03-21 2016-02-18 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
US20160052912A1 (en) * 2013-03-21 2016-02-25 Bayer Pharma Akitiengesellschaft Diaminoheteroaryl substituted indazoles
CN105408324A (zh) 2013-06-21 2016-03-16 拜耳制药股份公司 取代的苄基吡唑
EP3010901B1 (en) 2013-06-21 2017-09-13 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
JP2016536311A (ja) 2013-10-30 2016-11-24 バイエル ファーマ アクチエンゲゼルシャフト ヘテロアリール置換ピラゾール類
CA2935392C (en) 2014-01-01 2022-07-26 Medivation Technologies, Inc. Amino pyridine derivatives for the treatment of conditions associated with excessive tgf.beta activity
TW201613886A (en) 2014-06-17 2016-04-16 Bayer Pharma AG 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CN107148420A (zh) * 2014-09-19 2017-09-08 拜耳制药股份公司 苄基取代的吲唑类化合物
WO2016042084A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 inhibitors
CN107406417B (zh) 2015-01-28 2020-06-09 拜耳制药股份公司 4H-吡咯并[3,2-c]吡啶-4-酮衍生物
CA2989469A1 (en) 2015-06-17 2016-12-22 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
US20200216439A1 (en) * 2015-12-16 2020-07-09 Bayer Pharma Aktiengesellschaft Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
JP2023543528A (ja) 2020-09-23 2023-10-16 スコーピオン セラピューティクス インコーポレイテッド がんの処置に有用なピロロ［３，２－ｃ］ピリジン－４－オン誘導体
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
TW202229282A (zh) 2020-09-30 2022-08-01 美商史考皮恩治療有限公司 治療癌症之方法
CA3198202A1 (en) 2020-10-09 2022-04-14 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
EP4293019A1 (en) * 2022-06-13 2023-12-20 Netherlands Translational Research Center Holding B.V. 4-substituted (1h-benzo[d]imidazol-2-yl)-1h-pyrazoles as bub1 inhibitors useful for treating cancers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6837294B2 (en) * 2003-02-10 2005-01-04 Zipshade Industrial (B.V.I.) Corp. Pull down, push up, shade assembly
ES2351357T3 (es) * 2005-07-26 2011-02-03 Vertex Pharmaceuticals Incorporated Bencimidazoles útiles como inhibidores de proteínas cinasas.
JP2010111624A (ja) * 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
US20130178475A1 (en) * 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
JP5976778B2 (ja) * 2011-04-11 2016-08-24 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体
UA111754C2 (uk) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
JP6141866B2 (ja) * 2011-12-21 2017-06-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換ベンジルピラゾール類
DE102012200352A1 (de) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
US20150141372A1 (en) * 2012-05-11 2015-05-21 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
US20160046604A1 (en) * 2013-03-21 2016-02-18 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
US20160052912A1 (en) * 2013-03-21 2016-02-25 Bayer Pharma Akitiengesellschaft Diaminoheteroaryl substituted indazoles

Also Published As

Publication number Publication date
CN105209455A (zh) 2015-12-30
CA2907592A1 (en) 2014-09-25
JP2016514718A (ja) 2016-05-23
AR095706A1 (es) 2015-11-04
US20160046610A1 (en) 2016-02-18
WO2014147203A1 (en) 2014-09-25
HK1218750A1 (zh) 2017-03-10
TW201514166A (zh) 2015-04-16
EP2976336A1 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
UY35500A (es) Indazoles sustituidos con heteroarilo
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
DOP2017000176A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2016000925A1 (es) Inhibidores de bromodominio
ECSP14013284A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CL2015002932A1 (es) Inhibidores de proteína quinasa
CR20150524A (es) Compuestos de heteroarilo y sus usos
CR20150462A (es) Inhibidores de erk y sus usos
CL2016000922A1 (es) Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
ECSP14033037A (es) Síntesis de compuestos heterocíclicos
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
UY35467A (es) Compuestos orgánicos
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
BR112016012146A8 (pt) derivados de aminopiridina como inibidores de quinase da família tam
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
BR112015019624A2 (pt) quinazolinas como inibidores de quinase
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206